Sec Form 13D Filing - Injective Foundation filing for - 2026-01-05

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D



Comment for Type of Reporting Person:
The percentages of Common Shares reported as beneficially owned are calculated based on an aggregate of 25,988,641 Common Shares issued and outstanding, including the 1,345,941 Common Shares issued and outstanding as of December 12, 2025, as set forth in the Issuer's Registration Statement on Form S-1 filed with the Securities and Exchange Commission (the "SEC") on December 12, 2025, plus the 24,642,700 Common Shares issued in the automatic exchange of Subscription Receipts as described therein and herein.


SCHEDULE 13D



Comment for Type of Reporting Person:
The percentages of Common Shares reported as beneficially owned are calculated based on an aggregate of 25,988,641 Common Shares issued and outstanding, including the 1,345,941 Common Shares issued and outstanding as of December 12, 2025, as set forth in the Issuer's Registration Statement on Form S-1 filed with the SEC on December 12, 2025, plus the 24,642,700 Common Shares issued in the automatic exchange of Subscription Receipts as described therein.


SCHEDULE 13D

 
Injective Foundation
 
Signature:/s/ Glenn Kennedy
Name/Title:Glenn Kennedy, Director
Date:01/02/2026
 
Glenn Kennedy
 
Signature:/s/ Glenn Kennedy
Name/Title:Glenn Kennedy
Date:01/02/2026
primary_doc.xml